Sponsors (5)
The bill increases federal investment and coordination to expand HPV vaccination, outreach, and cancer screening—improving prevention and equity for many Americans—while increasing federal spending, adding provider and implementation burdens, and leaving uncertainty about long-term funding and reach.
Adolescents (especially ages 9–12) will be more likely to receive HPV vaccination, reducing future HPV-related cancers and improving long-term health outcomes.
Women and racial/ethnic-minority and rural communities will receive targeted, culturally tailored outreach and improved screening coordination, which should reduce disparities in HPV-associated cancer incidence and detection.
Women eligible for the program will gain expanded breast and cervical cancer screening services backed by $300 million per year (FY2026–2030), improving early detection and treatment opportunities.
Taxpayers and the federal budget will face increased costs (about $1.5 billion over FY2026–2030 plus an awareness campaign budget), which could affect deficits or require offsets elsewhere.
Women, rural and low-income communities may still face access gaps if vaccination and screening expansion are not fully matched with resources or outreach, risking uneven benefits and persistent disparities.
Healthcare providers will face added burden to implement counseling, reminder systems, and outreach activities, which could strain clinic time and resources.
Based on analysis of 4 sections of legislative text.
Requires a CDC national HPV awareness campaign ($5M/yr, FY2026–2030), mandates a 2027 report, and adds $300M/yr (FY2026–2030) for breast and cervical cancer screening.
Introduced December 10, 2025 by Kathy Castor · Last progress December 10, 2025
Requires the Centers for Disease Control and Prevention to run a national public awareness campaign to increase knowledge about HPV, counter misinformation, and raise HPV vaccine initiation and completion, with grants to states, tribes, local public health departments, and nonprofits. Provides dedicated federal funding for the campaign ($5 million per year, FY2026–2030), requires HHS to report on the campaign's activities and impacts, and increases mandatory funding for the Breast and Cervical Cancer Early Detection Program by $300 million per year for FY2026–2030 (in addition to retaining a prior $75 million line). The bill also makes unspecified technical edits to a coordinating committee provision.